HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection.

AbstractRATIONALE:
Invariant natural killer T (iNKT) cells are a unique subset of T cells that recognize lipid antigens presented by CD1d molecules. Recent studies have shown that iNKT cells can protect mice against Mycobacterium tuberculosis (Mtb) infection. We sought to determine whether pharmacological activation of iNKT cells by α-galactosylceramide (α-GalCer) could be used to treat tuberculosis (TB).
OBJECTIVES:
We hypothesized that α-GalCer, either alone or in combination with isoniazid, could be used to treat pulmonary TB.
METHODS:
The ability of α-GalCer-activated iNKT cells to suppress Mtb replication was evaluated using an in vitro coculture system. To test its potency in vivo, mice infected with virulent Mtb were treated with α-GalCer alone or in combination with isoniazid.
MEASUREMENTS AND MAIN RESULTS:
Quantitative colony-forming unit counts were compared for both experimental systems. Our results show that α-GalCer plus isoniazid controls bacterial growth better than α-GalCer or INH alone, and single or multiple α-GalCer administrations prolong the survival of the mice infected via the aerosol route.
CONCLUSIONS:
Our results demonstrate that α-GalCer administration can improve the outcome of Mtb infection, even when transmitted by the aerosol route. However, a combination of isoniazid and α-GalCer treatment has a synergistic effect on infection control. We conclude that more efficient treatment of TB will be achieved through a combination of classic chemotherapy and modulation of the host immune response.
AuthorsIsabel Sada-Ovalle, Markus Sköld, Tian Tian, Gurdyal S Besra, Samuel M Behar
JournalAmerican journal of respiratory and critical care medicine (Am J Respir Crit Care Med) Vol. 182 Issue 6 Pg. 841-7 (Sep 15 2010) ISSN: 1535-4970 [Electronic] United States
PMID20508216 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD1d
  • Antitubercular Agents
  • Galactosylceramides
  • alpha-galactosylceramide
  • Isoniazid
Topics
  • Animals
  • Antigens, CD1d (immunology)
  • Antitubercular Agents (therapeutic use)
  • Drug Therapy, Combination
  • Female
  • Galactosylceramides (therapeutic use)
  • Immunomodulation
  • Isoniazid (therapeutic use)
  • Mice
  • Mice, Inbred C3H
  • Mice, Inbred C57BL
  • Mycobacterium tuberculosis (drug effects, immunology)
  • Natural Killer T-Cells (immunology)
  • Treatment Outcome
  • Tuberculosis, Pulmonary (drug therapy, immunology, microbiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: